Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which extra drop works best for glaucoma patients?

NCT ID NCT06449352

Disease control Sponsor: Westlake Eye Specialists Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 100 adults with normal tension glaucoma who were already using the eye drop latanoprost. Researchers added either netarsudil or brimonidine to see which combination lowered eye pressure more effectively. The goal was to find a better way to control the disease and prevent vision loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

100 people

The number who actually took part.

Started

Jun 2024

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients 18 years and older * Diagnosed with normal tension glaucoma based on the following: * IOP ≤ 21mmHg * Optic nerve rim thinning and/or retinal nerve fiber layer (RNFL) loss consistent with glaucoma * Normal visual field OR visual field loss consistent with optic nerve or RNFL defects within the last year * Open angles assessed by gonioscopy * Have been on latanoprost monotherapy for at least 6 weeks Exclusion Criteria: If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study. * Patients with angle closure glaucoma or secondary forms of glaucoma due to neovascularization of the angle, uveitic glaucoma, congenital glaucoma, or glaucoma due to congenital anomalies. * Other forms of secondary glaucoma. * Patients with abnormal anterior segment examination other than cataract will be excluded from the study. * Patients who have had incisional surgery for glaucoma (eg: MIGs). * Patients with refractory CME or CME persisting 3 months or more. * Children, cognitive impaired and critically ill subjects will not be enrolled. * Central Corneal Thickness (CCT) ≤ 500. * Prior allergy to brimonidine or netarsudil, and known to have previously failed either brimonidine or netarsudil. * Ocular surgery (e.g., cataract, laser, refractive) during the study or 1 year prior to entering the study. The principal investigator reserves the right to declare a patient ineligible or non- evaluable based on medical evidence that indicates they are unsuitable for the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Normal tension glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

low tension glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Normal tension glaucoma

Contacts and locations

Locations

  • Westlake Eye Specialists - Austin Office

    Austin, Texas, 78746, United States

  • Westlake Eye Specialists - Killeen Office

    Killeen, Texas, 76549, United States

  • Westlake Eye Specialists - Kyle Office

    Kyle, Texas, 78640, United States

  • Westlake Eye Specialists - New Braunfels Office

    New Braunfels, Texas, 78130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.